Drug Profile

ABG 023

Alternative Names: AB-G023

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AmideBio
Class Antihypoglycaemics; Pancreatic hormones
Mechanism of Action Glucagon receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Congenital hyperinsulinism
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Congenital hyperinsulinism

Most Recent Events

28 May 2024 No recent reports of development identified for preclinical development in Congenital-hyperinsulinism in USA
20 Aug 2020 ABG 023 receives rare pediatric disease designation for Congenital-hyperinsulinism in USA
28 Apr 2020 ABG 023 is available for licensing as of 28 Apr 2020. https://www.amidebio.com/ (AmideBio website, April 2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com